GlassScriptPhysician profile
Joseph Prohaska
NPI 1790158012
$10,933.79
in general payments reported to CMS, 2019-2025
38 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 87% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $1,256 · 2021: $1,634 · 2022: $1,454 · 2023: $1,614 · 2024: $2,286 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,634 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,634.24 |
| Education | $189.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,533.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,516.75 | 2019-2025 | |
| Lilly USA, LLC | $1,469.04 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $849.05 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $787.61 | 2020-2025 | Ilumya |
| Ucb, INC. | $687.57 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $528.95 | 2020-2025 | Otezla |
| Leo Pharma INC. | $411.56 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $365.19 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $185.52 | 2019-2023 | |
| Genentech USA, INC. | $159.48 | 2021-2022 | |
| Genzyme Corporation | $158.56 | 2021-2022 | |
| Dermavant Sciences, INC. | $153.05 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $109.15 | 2024-2025 | Nemluvio, Aklief |
| Merz North America, INC. | $101.78 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Prohaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.